touchONCOLOGY joins Dr Yelena Janjigian (Medical Oncologist, Chief, Memorial Sloan Kettering Cancer Center, New York, NY, USA) at ASCO 2021 to discuss durvalumab in gastric cancer and the MATTERHORN study.
The abstract ‘A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03) (NCT04379596)’ (abstract number TPS261) was presented at the 2021 ASCO Annual Meeting.
Citation: J Clin Oncol 39, 2021 (suppl 3; abstr TPS261)
DOI: 10.1200/JCO.2021.39.3_suppl.TPS261
Questions
1. What is the rationale for the addition of durvalumab to neoadjuvant-adjuvant FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer? (00:15-01:45)
2. What are the eligibility criteria and key inclusion criteria for the MATTERHORN study? (01:45-04:30)
3. Could you give us a brief overview of the study design? (04:30-06:26)
4. What are the primary and secondary study endpoints? (06:26-06:50)
5. When are initial results expected? (06:50-07:10)
Disclosures: Research Funding: NCI, Department of Defense, Cycle for Survival, Fred’s Team, RGENIX, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly and Merck. Advisory Boards/Consulting: Bristol-Myers Squibb, Merck Serono, Merck, Eli Lilly, Daiichi-Sankyo, Pfizer, Bayer, Imugene, AstraZeneca, Zymeworks Inc., Seattle Genetics, Basilea Pharmaceutica, RGENIX (stock options and consulting).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
